Earnings Data
Report Date
Jul 29, 2026After Close (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
0.97Last Year’s EPS
1.01Same Quarter Last Year
Based on 4 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
The call presented a mixed but constructive view: near‑term headwinds included modest revenue declines on a reported basis, lower adjusted net income and EPS, weaker cash from operations and higher working capital as inventory was intentionally built. Offsetting these concerns were upgraded organic revenue guidance (5.0%–6.5%), clear momentum in core growth platforms (AirSeal, Buffalo Filter direct smoke, BioBrace), improved gross margin (up 100 bps) and maintained full‑year adjusted EPS guidance despite a planned refinancing headwind. Management also completed GI divestitures to focus resources and continued buybacks. Overall the transcript shows cautious optimism with tangible operational and strategic progress balanced against short‑term financial pressures.Company Guidance
Raised Organic Revenue Guidance
Organic revenue guidance for FY2026 was raised to 5.0%–6.5% (from prior 4.5%–6.0%), with FX now expected to be a ~40–50 bps tailwind; reported 2026 revenue guidance increased at the low end to $1.35B–$1.375B and Q2 revenue is expected to be $336M–$340M.
Platform Momentum — Orthopedics and BioBrace
Orthopedics grew 4.5% worldwide in Q1 (U.S. +5.5%, international +3.9%); BioBrace showing strong adoption with >30 published studies and a 268‑patient RCT on track to complete enrollment in 2026 (publication expected 2027); orthopedics delivered its third consecutive quarter of at least mid‑single‑digit growth.
AirSeal Traction and Large TAM
AirSeal installed base exceeded 10,000 systems; continued Q1 growth with U.S. laparoscopic penetration only ~6%–7% of ~3 million annual procedures (indicating a large runway); management expects AirSeal to deliver high single‑digit to low double‑digit growth over the long term.
Buffalo Filter Growth Drivers and Regulatory Tailwind
Direct smoke evacuation grew in Q1 and remains a strategic focus; 20 U.S. states have smoke‑free OR laws covering ~51% of the population, providing legislative tailwinds; PlumeSafe X5 continues to gain traction in outpatient/ASC settings.
Improved Gross Margin
Adjusted gross margin in Q1 was 57.4%, improving 100 basis points year‑over‑year driven by favorable product mix and FX, and management reiterated a full‑year gross margin improvement target of 50–100 bps.
Capital Allocation Discipline — Buybacks and M&A Focus
Q1 share repurchases totaled ~858,000 shares for $37.4M; company re‑iterated priorities of organic investment, disciplined acquisitions aligned to platforms, and returning capital to shareholders while strengthening the balance sheet.
Strategic Portfolio Simplification and Supply Chain Progress
Completed divestitures of remaining GI product lines to sharpen focus on higher‑growth, higher‑margin platforms (GI revenue now expected $14.5M–$17.5M in 2026); supply chain performance improved with intentionally higher inventory to support service levels and allowed sales teams to go on offense.
DE:EC8 Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
DE:EC8 Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Apr 29, 2026 | €30.60 | €31.00 | +1.31% |
Jan 28, 2026 | €32.40 | €31.20 | -3.70% |
Nov 05, 2025 | €38.60 | €38.20 | -1.04% |
Jul 30, 2025 | €43.04 | €43.44 | +0.93% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Conmed (DE:EC8) report earnings?
Conmed (DE:EC8) is schdueled to report earning on Jul 29, 2026, After Close (Confirmed).
What is Conmed (DE:EC8) earnings time?
Conmed (DE:EC8) earnings time is at Jul 29, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Conmed stock?
The P/E ratio of Conmed is N/A.
What is DE:EC8 EPS forecast?
DE:EC8 EPS forecast for the fiscal quarter 2026 (Q2) is 0.97.